SCHEMBL1763992

SCHEMBL1763992

CC(C)N(C(C)C)P(O)OC(C)(C#N)C#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6513766 0.94
SCHEMBL1763990 0.78
SCHEMBL1603737 0.75
SCHEMBL9494298 0.72
SCHEMBL1004709 0.69
SCHEMBL994101 0.69
SCHEMBL26187546 0.67
SCHEMBL9494293 0.66
SCHEMBL1763993 0.64
SCHEMBL7858703 0.64 TSHR (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4717779-A2 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TriLink BioTechnologies, LLC (US) 2026-04-01 EP disclosed
EP-4276189-B1 INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES LLC (US) 2026-04-01 EP disclosed
EP-4424835-B1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES LLC (US) 2026-01-21 EP disclosed
EP-4658664-A1 CAP ANALOGS WITH 5'-TERMINAL ACYCLIC GUANOSINE DERIVATIVE CureVac SE (DE) 2025-12-10 EP disclosed
US-20250171489-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES, LLC (US) 2025-05-29 US disclosed
US-12258369-B2 Compositions and methods for synthesizing 5′-capped RNAs TRILINK BIOTECHNOLOGIES, LLC (US) 2025-03-25 US disclosed
US-20240383938-A1 PHOSPHOROAMIDATE ESTERS, AND USE AND SYNTHESIS THEREOF ROCHE SEQUENCING SOLUTIONS INC (US) 2024-11-21 US disclosed
US-12103944-B2 Compositions and methods for synthesizing 5′-capped RNAs TRILINK BIOTECHNOLOGIES, LLC (US) 2024-10-01 US disclosed
EP-4424835-A2 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TriLink BioTechnologies, LLC (US) 2024-09-04 EP disclosed
WO-2024160895-A1 CAP ANALOGS WITH 5'-TERMINAL ACYCLIC GUANOSINE DERIVATIVE CureVac SE (DE) 2024-08-08 WO disclosed
US-20120264924-A1 Glycorandomization and Production of Novel Novobiocin Analogs WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-10-18 US disclosed
US-8198419-B2 Glycorandomization and production of novel erythromycin analogs WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-06-12 US disclosed
US-20110124850-A1 Glycorandomization and Production of Novel Vancomycin Analogs THORSON JON 2011-05-26 US disclosed
EP-1138782-B1 Multiplex sequence variation analysis of DNA samples by mass spectrometry BRUKER DALTONIK GMBH (DE) 2010-10-20 EP disclosed
US-20090023594-A1 REAGENTS FOR LABELLING NUCLEIC ACIDS AND USES THEREOF EXIQON A/S (DK) 2009-01-22 US disclosed
US-20080268504-A1 Glycorandomization and Production of Novel Vancomycin Analogs WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-10-30 US disclosed
US-7348309-B2 Glycorandomization and production of novel vancomycin analogs WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-03-25 US disclosed
US-20040259228-A1 Glycorandomization and production of novel vancomycin analogs WISCONSIN ALUMNI RESEARCH FOUNDATION 2004-12-23 US disclosed
US-20010038070-A1 Multiplex sequence variation analysis of DNA samples by mass spectrometry BRUKER SAXONIA ANALYTIK GMBH (DE) 2001-11-08 US disclosed
EP-1138782-A2 Multiplex sequence variation analysis of DNA samples by mass spectrometry BRUKER-SAXONIA ANALYTIK GMBH (DE) 2001-10-04 EP disclosed